NeoGenomics Reports Strong Q1 2026 Earnings with Revenue and EBITDA Growth
NeoGenomics reported Q1 2026 revenue of $186.7 million, up 11% year-over-year, with adjusted EBITDA rising 27% to $9.0 million. The company raised its full-year revenue guidance to $797–803 million and highlighted strong growth in clinical and NGS revenue, as well as early traction with new products like RaDaR ST and PanTracer.
Tickers: $NEO
Topics: Clinical Testing Earnings EBITDA Financial Guidance NGS Product Launch Revenue Growth